Improving Obesity Care and Management

Program Overview

by Chair, Marc-Andre Cornier, MD

As a supplemental course to the Endocrine Society’s Fellows Training Series (FTS), this course focuses on understanding the pathophysiology of obesity, understanding obesity stigma and improving patient conversations, incorporating motivational interviewing techniques, the utility of different dietary interventions in weight management and the role of behavior in dietary modification, the challenges of initiating and maintaining physical activity, polypharmacy in weight management, and surgical and endoscopic approaches to weight loss. It is targeted to deliver comprehensive education on practical aspects of patient care through interactive and multi-faceted learning opportunities. This course series features 6 programs providing free continuing medication education credit. You can take courses individually or the entire package dependent on your learning needs. 

As leaders in endocrinology and obesity medicine, Endocrine Society and The Obesity Society are collaborating to address knowledge, skill, and workforce gaps surrounding obesity care and management. By offering an interactive and multi-faceted learning opportunity, this program delivers comprehensive education on practical aspects of patient care.  We thank Novo Nordisk for generously supporting this program.

Each module will include:

  • Recorded presentations
  • Knowledge, skill, or perception questions
  • Clinical case vignettes
  • Answer comparisons
  • Additional Practice Resources


  1. Understanding the Pathophysiology of Obesity & the Weight Reduced State
  2. Shepherding the Difficult Conversation & Assessing the Patient with Obesity
  3. Lifestyle Prescription: Behavior and Nutrition
  4. Lifestyle Prescription: Behavior and Physical Activity
  5. Updates in the Landscape and Application of Pharmacotherapy
  6. Surgical and Endoscopic Approaches to Weight Loss

Learning Objectives

Upon completion of this course learners will be able to:

  • Review and identify the available and emerging therapeutic approaches to obesity.
  • Gain working knowledge of new medications in the pipeline to treat and manage obesity. 
  • Review different approaches to weight loss/maintenance and discuss methods necessary to improve patient treatment adherence.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Topic Area: 
Level of Outcomes: 
Level 1 (Participation)
Activity summary
Course opens: 
Course expires: 
1Daniel Bessesen, MDUnderstanding the Pathophysiology of Obesity & the Weight Reduced State
2Scott Kahan, MD, MPHShepherding the Difficult Conversation & Assessing the Patient with Obesity
3Jamy D. Ard, MDLifestyle Prescription: Behavior and Nutrition
4John M. Jakicic, PhDLifestyle Prescription: Behavior and Physical Activity 
5Marc-Andre Cornier, MDUpdates in the Landscape and Application of Pharmacotherapy
6Sangeeta Kashyap, MDSurgical and Endoscopic Approaches to Weight Loss

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported no relevant financial relationships: Daniel Bessesen, MD, Scott Kahan, MD, MPH, Sangeeta Kashyap, MD

The following faculty reported  relevant financial relationships during the content development process for this activity:  

  • Jamy D. Ard, MD, Consultant, Nestle Healthcare Nutrition
  • John M. Jakicic, PhD, Advisory Board, WW International, Inc.
  • Marc-Andre Cornier, MD, Research Investigator, Rhythm Pharmaceutical

The following SPC Committee members reported financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member, Corcept
  • Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
  • Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
  • Amy Rothberg, MD: Spouse, consultant of Merck
  • Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

Beret Ann Casey, MD; Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS USE OF PROFESSIONAL JUDGMENT: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT This educational activity is supported by an independent medical educational grant from Novo Nordisk, Inc.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.



AMA PRA Category 1 Credit:

The Endocrine Society designates this enduring activity for a maximum of 7.0 AMA PRA Category 1 Credits™., 1.0 Credit for completion of each of the seven activity modules.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC):

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.0 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program, 1.0 Point for completion of each of the seven activity modules. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.